Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Molecular Cancer Therapeutics|April 28, 2025
The anti-FRα antibody-drug conjugate luveltamab tazevibulin demonstrates efficacy in non-small cell lung cancer preclinical models and induces immunogenic cell deathRobert Yuan, Andrew McGeehan, Sihong Zhou, et al.
Cell|October 16, 2012
Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier functionJing Jin, Karen Sison, Chengjin Li, et al.
Cancer Immunology, Immunotherapy : CII|October 26, 2017
A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in miceTimothy S Fisher, Andrea T Hooper, Justin Lucas, et al.
Molecular Cancer Therapeutics|December 11, 2012
Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cellsPuja Sapra, Marc Damelin, John Dijoseph, et al.
The AAPS Journal|April 26, 2017
Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug ConjugatesL Nathan Tumey, Fengping Li, Brian Rago, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2007
Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodiesHans-Peter Gerber, Xiumin Wu, Lanlan Yu, et al.
Bioconjugate Chemistry|July 15, 2016
Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) PayloadsSujiet Puthenveetil, Frank Loganzo, Haiyin He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2020
Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid LeukemiaYoon-Chi Han, Jennifer Kahler, Nicole Piché-Nicholas, et al.
Cell Reports. Medicine|June 7, 2021
NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cellsKenneth G Geles, Yijie Gao, Andreas Giannakou, et al.
Molecular Cancer Therapeutics|July 6, 2022
Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint BlockadeAndrea T Hooper, Kimberly Marquette, Chao-Pei Betty Chang, et al.
Pageof 8